PhaseBio Pharmaceuticals Logo in transparent PNG and SVG formats

PhaseBio Pharmaceuticals Logo large

PhaseBio Pharmaceuticals Logo icon format

PhaseBio Pharmaceuticals Logo large for dark backgrounds

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

  • Website domain:
  • Employees: 60
  • Marketcap: $3.49 Million USD

Page last updated on:

May 11th, 2023